At a glance
ClinicalIndex Comparison Record- ✓Age 1 to 18 years (inclusive)
- ✓Diagnosis of non-B-cell ALL confirmed by immunophenotyping with flow cytometry, morphology, and cytochemical staining
- ✕Prior chemotherapy treatment for one week or longer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
In Brief
A Phase 3 clinical trial evaluating Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, and 4 other interventions for Lymphoblastic Leukemia, Acute. Completed, enrolled 501 participants across 2 sites.
Detailed Summary
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
Study Details
Timeline
Interventions
See Detailed Description sections for details on treatment interventions.
See Detailed Description sections for details on treatment interventions.
See Detailed Description sections for details on treatment interventions.
See Detailed Description sections for details on treatment interventions.
See Detailed Description sections for details on treatment interventions.
See Detailed Description sections for details on treatment interventions.